Pasireotide — drug · CancerIndex

Regulatory

Approvals (4)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

openfdaRegulatory4 approval records · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
US FDA	—	Efficacy supplement 2020-01-15 (see label)	approved	Jan 15, 2020	openfda
US FDA	—	Efficacy supplement 2018-06-29 (see label)	approved	Jun 29, 2018	openfda
US FDA	—	Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. • Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.	approved	Dec 15, 2014	openfda
US FDA	—	Cushing's Disease SIGNIFOR is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.	approved	Dec 14, 2012

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	3	2	4	28	4	US	Dec 14, 2012	2004-01
Malignant Prostate Neoplasm	Phase4	Phase 4	0	0	0	4	0	—	—	2011-06
Malignant Pancreatic Neoplasm	Phase3	Phase 3	0	0	1	1	0	—	—	2009-10
Malignant Breast Neoplasm	Phase2	Phase 2	0	0	0	1	0	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
SSTR5 Overexpression1
Pasireotide	Neuroendocrine Tumor

Clinical trials

Trials with this intervention (28)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–28 of 28 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06295952	A Study of Pasireotide in People With Prolactinoma	recruiting	Phase 2	10	Memorial Sloan Kettering Cancer CenterOTHER	1	Mar 4, 2026	clinicaltrials
NCT01313559	Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer	terminated	Phase 2